Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 16,400 shares, a decrease of 34.4% from the December 15th total of 25,000 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upgraded Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.

Basilea Pharmaceutica Price Performance

OTCMKTS:BPMUF remained flat at $52.83 during trading hours on Thursday. The business has a 50 day simple moving average of $52.83 and a two-hundred day simple moving average of $51.08. Basilea Pharmaceutica has a 12-month low of $38.60 and a 12-month high of $52.83.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.